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Risk factors of ocular involvement in children with 
mitochondrial respiratory chain complex defect
Purpose: Mitochondrial dysfunction can present with various 
symptoms depending on the organ it has affected. This research 
tried to analyze the ophthalmologic symptoms and ophthalmologic 
examination (OE) results in patients with mitochondrial disease (MD). 
Methods: Seventy-four patients diagnosed with mitochondrial 
respiratory chain complex defect with biochemical enzyme assay 
were included in the study. They were divided into 2 groups based on 
the OE results by funduscopy and were analyzed on the basis of their 
clinical features, biochemical test results, morphological analysis, and 
neuroimaging findings.
Results: Thirty-seven (50%) of the 74 MD patients developed 
ophthal mologic symptoms. Abnormal findings were observed in 36 
(48.6%) patients during an OE, and 16 (21.6%) of them had no ocular 
symptoms. Significantly higher rates of prematurity, clinical history of 
epilepsy or frequent apnea events, abnormal light microscopic findings 
in muscle pathology, diffuse cerebral atrophy in magnetic resonance 
imaging, and brainstem hyperintensity and lactate peaks in magnetic 
resonance spectroscopy were noted in the group with abnormal OE 
results.
Conclusion: Although the ophthalmologic symptoms are not very 
remarkable in MD patients, an OE is required. When the risk factors 
mentioned above are observed, a more active approach should be 
taken in the OE because a higher frequency of ocular involvement can 
be expected.
Key words: Mitochondria, Ophthalmology, Retina, Funduscopy, Risk 
factor
Jung Hyun Chae, M.D.1, Jung Hun Lee, M.D.1, 
Kyo Ryung Kim, M.D.1, Suk Ho Byeon, M.D.2, 
Young Mock Lee, M.D.1, Hoon Chul Kang, 
M.D.1, Joon Soo Lee, M.D.1, and Heung Dong 
Kim, M.D.1
Department of Pediatrics1, Gangnam Severance Hos­
pital, Severance Children's Hospital, Yonsei University 
College of Medicine, Seoul, 
The Institute of Vision Research2, Department of 
Ophthalmology, Severance Hospital, Yonsei University 
College of Medicine, Seoul, Korea
Received: 15 September 2010, Revised: 11 October 2010
Accepted: 3 November 2010
Corresponding author: Young Mock Lee, M.D.
Department of Pediatrics, Gangnam Severance Hospital, 
Severance Children's Hospital, Yonsei University College of 
Medicine, PO Box 1217, 712 Eonjuro, 146-92 Dogok-dong, 
Gangnam-gu, Seoul 135-720, Korea 
Tel: +82.2-2019-3354, Fax: +82.2-3461-9473
E-mail: ymleemd@yumc.yonsei.ac.kr
Copyright © 2010 by The Korean Pediatric Society
This is an open­access article distributed under the terms of the Creative Commons Attribution Non­Commercial License (http://creativecommons.org/licenses/by­
nc/3.0/) which permits unrestricted non­commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
chain complex (MRC) that exists within its inner membrane1, 2). 
Mitochondrial dysfunctions can happen in virtually any type of 
tissue or any organ, though they most commonly present with 
abnormal symptoms related with the neuromuscular system3, 4). In 
Introduction
Mitochondria produce energy to maintain cellular functions 
through the oxidative phosphorylation of mitochondrial respiratory 
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short, they present with a variety of symptoms depending on the 
organ they have involved5, 6).
Thus far, there have been many reports on the ophthalmologic 
involvement of mitochondrial diseases (MD)7, 8). A variety of ocular 
symptoms and signs, such as pigmentary retinal degeneration, 
external ophthalmoplegia, and optic atrophy, are observed in 
patients with MD. Optic nerve, retina, pigment epithelium, 
and ocular tissues are reported to be dependent on oxidative 
energy production9, 10), and some relationship between specific 
ophthalmologic diseases and MD have also been suggested11­13).
While there have been many reports and experiments published 
on ophthalmologic manifestations of MD, few studies have 
been conducted on the related factors themselves that affect the 
manifestation. This research tried to analyze the ophthalmologic 
symptoms and ophthalmologic examination (OE) results of 
patients with MD to better understand their relationship.
Materials and method
1. Patients
The study was conducted with seventy­four patients who had 
been diagnosed as having MRC defect at the Gangnam Severance 
Hospital from September 2005 to March 2008. The study was 
approved by the institutional review board of our hospital and 
written informed consent was obtained from all patients. Evaluation 
of MRC dysfunction was performed by analyzing the activities of 
reduced nicotinamide adenine dinucleotide (NADH)­coenzyme 
Q (CoQ) reductase (complex I), succinate­CoQ reductase (complex 
II), succinate­cytochrome c reductase (complex II­III), cytochrome 
c reductase (complex III), cytochrome c oxidase (complex IV), 
oligomycin­sensitive ATPase (complex V), and citrate synthase 
assessed from isolated mitochondria in muscle tissue through use of 
standard spectrophotometric assays as described by Rustin, et al14). 
We defined MRC defect as reduction of residual enzyme activity 
below 20% of controls.
2. Clinical evaluation 
Ophthalmologic symptoms were initially evaluated by inquiring 
about the subjects’ medical history, followed by a neurological 
examination. Ophthalmologists performed an OE with a 
funduscopy after dilating the pupils. The seventy­four patients were 
divided into two groups based on the results of fundus examination 
as either a normal or abnormal group. The two groups were then 
compared and analyzed based on their clinical features, biochemical 
test, morphological analysis, and neuroimaging findings. 
Lactic acidosis was diagnosed as a serum lactate higher than 2.2 
mmol/L. Increased lactate/pyruvate ratio was defined when it was 
higher than 20, and cerebrospinal fluid (CSF) lactate levels when 
it was higher than 22 mg/dL. Urine organic acid metabolites were 
interpreted as a mitochondrial dysfunction when lactic aciduria 
was accompanied with an elevation of Kreb cycle metabolites, such 
as 3­methylglutaconic acid, ethylmalonic acid, dicarboxylic acid, 
tiglylglycine, butyrylglycine, 2­ethylhydracrylic, 2­methylsuccinate, 
and isovalerylglycine. In plasma amino acid assays, special attention 
was paid to the secondary hyperalaninemia derived from lactic 
acidemia. The mitochondrial fatty acid disorder was analyzed 
through the evaluation of plasma acylcarnitine profile screen15, 16).
In the morphological analysis, light microscopic observation 
confirmed ragged red fibers by a modified Gomori trichrome 
stain. Succinate dehydrogenase, NADH, ATPase, Periodic 
acid Schiff (PAS), and lipid stain were all performed for the 
immunohistochemical examination. Electron microscopic 
observation confirmed abnormal mitochondrial structures, including 
the proliferation of the cristae mitochondriales, paracrystalline 
inclusions, or mitochondrial proliferation with an accumulation of 
excessive or enlarged mitochondria in the subsarcolemmal regions17).
3. Statistical analysis
The chi­squared test and independent t­test were used to interpret 
the data, and a P­value of less than 0.05 was used to determine 
statistical significance.
 Results
1. Ophthalmologic symptoms & examination 
Thirty­seven (50%) out of the seventy­four MD patients 
developed ophthalmologic symptoms. Abnormal findings were 
observed in thirty­six (48.6%) patients during the OE, and sixteen 
Table 1. Ophthalmologic Symptoms and Ophthalmologic Examination 
Findings of Mitochondrial Disease Patients
Ophthalmologic symptom
(n=74) (%)
Ophthalmologic examination 
(n=74) (%)
Abnormal symptoms 37 (50.0)
  Nystagmus            15 (20.3)
  Strabismus            14 (18.9)
  Visual disturbance 10 (13.5)
  Ptosis                    6 (  8.1)
  Ophthalmoplegia        5 (  6.8)
  Entropion                 2 (  2.7)
  Epiblepharon              3 (  4.1)
Nonspecific symptoms 37 (50.0)
Abnormal findings 36 (48.6)
  Mild retinal pigmentation 18 (24.3)
  Pale disc 11 (14.9)
  Vessel tortuosity   5 (  6.8)
  Wide retinal pigmentation   3 (  4.1)
  Optic nerve atrophy    2 (  2.7)
  Tigroid fundus   2 (  2.7)
  Retinopathy of prematurity   2 (  2.7)
  Hyperplastic macula   1 (  1.4)
  Cataract   1 (  1.4)
  Peripapillary atrophy   1 (  1.4)
  Periretinal hemorrhage   1 (  1.4)    
Normal findings  38 (51.4)
996     JH Chae, et al. • Ocular involvement in mitochondrial disease
(21.6%) of them had not experienced ocular symptoms. Among 
patients with ophthalmologic symptoms, fifteen patients (20.3%) 
had nystagmus, fourteen had (18.9%) strabismus, ten had (13.5%) 
visual disturbance, six had (8.1%) ptosis, and five had (6.8%) 
opthalmoplegia. Among the patients with abnormal findings in 
the OE, eighteen patients (24.3%) had mild retinal pigmentation, 
eleven had (14.9%) pale disc, five had (6.8%) vessel tortuosity, 
three had (4.1%) wide retinal pigmentation, two had (2.7%) optic 
nerve atrophy, two had (2.7%) tigroid fundus, two had (2.7%) 
retinopathy of prematurity, one had (1.4%) hyperplastic macula, 
one had (1.4%) cataract, peripapillary atrophy, and one had (1.4%) 
periretinal hemorrhage (Table 1).
2. Demographics of patients 
The mean age of the abnormal OE group was 5.7±5.1 years, 
and that of the normal OE group was 5.2±3.4. The male to female 
ratio of the abnormal OE group was 1:1 and that of the normal 
OE group was 1.5:1. There was no significant difference regarding 
family history for the presence of MD or unexplained early deaths. 
No significant differences in the frequency of perinatal asphyxia, 
neonatal jaundice, or intrauterine growth retardation were noted 
between the two groups. But the history of prematurity was noted 
in eight patients in the abnormal OE group, significantly higher 
in prevalence compared to the normal OE group. However, there 
was no significant difference between the two groups regarding the 
prevalence of febrile convulsion, central nervous system, and head 
trauma (Table 2). 
3. Clinical manifestations 
The abnormal OE group had a statistically higher number of 
patients, twenty­six (72.2%), suffering epilepsy, while the normal 
OE group had only eighteen (47.4%). There was no significant 
difference regarding failure to thrive, delayed development, 
and muscle weaknesses. Hepatobiliary, cardiologic, and 
hematologic symptoms were also observed in both groups, but 
without significant difference. Frequent apnea events appeared 
in five patients (13.9%) in the abnormal OE group, indicating a 
statistically significant higher prevalence, but there was no other 
pulmonary symptom of any significant difference. No significant 
difference in gastrointestinal symptoms was observed between 
either of the two groups (Table 3).
4. Metabolic screening test, morphological analysis and 
biochemical enzyme assay 
There were twenty­eight (77.8%) patients in the abnormal 
OE group and thirty­two (84.2%) in the normal OE group who 
showed the presence of lactic acidosis. Also, seventeen patients 
(47.2%) of the abnormal OE group and twenty­four patients 
(63.2%) of the normal OE group showed an increase in their 
lactate/pyruvate ratio, but with no significant difference. Increased 
lactate in CSF, abnormal urine organic acids, and abnormal 
Table 2. Patient Demographics of Mitochondrial Disease Patients
 
Abnormal 
OE group 
(n=36) (%)
Normal 
OE group
(n=38) (%)
Total 
(%)
P-
value
Age (mean±SD, years)
Male:Female
Family history
Birth history 
  Prematurity
  Perinatal asphyxia
  Neonatal jaundice
  Intrauterine growth retardation 
Past history
  Febrile convulsion 
  Central nervous system infection 
  Head trauma 
5.7±5.1
18:18
0 (  0   )
8 (22.2)
7 (19.4)
5 (13.9)
5 (13.9)
6 (16.7)
4 (11.1)
1 (  2.8)
5.2±3.4
23:15
4 (10.5)
1 (  2.6)
5 (13.2)
3 (  7.9)
2 (  5.3)
4 (10.5)
1 (  2.6)
2 (  5.3)
5.5±4.3
41:33
  4 (  5.4)
  9 (12.2)
12 (16.2)
  8 (10.8)
  7 (  9.5)
10 (13.5)
  5 (  6.8)
  3 (  4.1)
0.669
0.363
0.115
<0.05
0.463
0.474
0.255
0.510
0.194
1.000
Abbreviations: OE, ophthalmologic examination; SD, standard deviation
Table 3. Clinical Manifestations of Mitochondrial Disease Patients
 
Abnormal 
OE group 
(n=36) (%)
Normal 
OE group
(n=38) (%)
Total 
(%)
P-
value
Neuromuscular symptom
  Epilepsy
  Failure to thrive
  Delayed development
  Muscle weakness
Hepatobiliary symptom
  Increased transaminase
  Hepatomegaly
  Liver failure
Cardiologic symptom
  Hypertrophic 
  Cardiomyopathy
  Heart failure
Hematologic symptom
  Anemia 
  Pancytopenia 
Pulmonary symptom
  Frequent apnea event
Recurrent pneumonia
  Ventilator care 
  Chronic cough          
Gastrointestinal symptom
  Frequent vomiting 
  Constipation
  Regurgitation
  Gastrointestinal bleeding
  Dysphagia  
26 (72.7)
14 (38.9)
33 (44.6)
16(44.4)
13 (36.1)
  2 (  5.8)
  0 (  0   )
  1 (  2.8)
  3 (  8.3)
10 (27.8)
  2 (  5.6)
  5 (13.9)
15 (41.7)
  8 (22.2)
  5 (13.9)
13 (36.1)
  5 (13.9)
11 (30.6)
  4 (11.1)
  1 (  2.8)
18 (47.4)
17 (44.7)
33 (44.6)
12 (31.6)
20 (52.6)
  0 (  0   )
  1 (  2.6)
  1 (  2.6)
  0 (  0   )
11 (52.4)
  3 (  7.9)
  0 (  0   )
10 (26.3)
  5 (13.2)
  1 (  2.6)
10 (26.3)
  3 (  7.9)
11 (29.0)
  1 (  2.6)
  0 (  0   )
44 (59.5)
31 (41.9)
66 (89.2)
28 (37.8)
33 (44.6)
  2 (  2.7)
  1 ( 1.4)
  2 (  2.7)
  3 (  4.1)
21 (28.4)
  5 (  6.8)
  5 (  6.8)
25 (33.8)
13 (17.6)
  6 (  8.1)
23 (31.1)
  8 (10.8)
22 (29.7)
  5 (  6.8)
  1 (  1.4)
<0.05
0.610
0.711
0.254
0.153
0.233
1.000
1.000
0.110
0.911
1.000
<0.05
0.163
0.306
0.103
0.363
0.474
0.880
0.194
0.487
Abbreviation: OE, ophthalmologic examination
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plasma amino acids were observed in both groups, but still with no 
significant difference. A morphological test was conducted using 
muscle samples. With a light microscope, abnormal findings were 
observed in thirteen patients (36.1%) in the abnormal OE group 
and six patients (15.8%) in the normal OE group implying that 
there was a statistically significant difference. But with an electron 
microscope, no statistical difference was noted between the two 
groups. The enzyme activity of the mitochondrial respiratory chain 
complex measured by biochemical assay of muscle samples also 
showed no significant difference between the two groups (Table 4).
5. Magnetic resonance imaging (MRI) and magnetic 
resonance spectroscopy (MRS) findings 
The MRI findings showed that nine patients (25.0%) in the 
abnormal OE group and two (5.2%) in the normal OE group 
had brainstem hyperintensity. Twenty­four patients (66.7%) 
in the abnormal OE group and eleven patients (29.0%) of the 
normal OE group had diffuse cerebral atrophy. Both findings were 
seen statistically more frequent in the abnormal OE group. No 
other MRI findings showed any significant difference. Among 
the seventy­two MRS examinees, lactate peaks were observed 
in twenty­one patients (60.0%) in the abnormal OE group and 
thirteen patients (35.1%) in the normal OE group. The difference 
was statistically significant (Table 5). 
Discussion
Thus far, there have been many studies regarding the ocular 
symptoms caused by MD7­10). We also noticed that 50% of the 
patients in our study suffered from ophthalmologic symptoms 
and 48.6% actually showed abnormal findings during an OE. 
In addition, sixteen (21.6%) of the patients with MRC defect but 
without ophthalmologic symptoms showed abnormal findings 
in the fundus examination, which emphasizes the importance 
of an active OE in MD even at the absence of any symptoms. 
The reason why there are plenty of ocular involvements observed 
in MD could be explained by the fact that the retinal pigment 
epithelium possesses a highly metabolically active cell type that has 
a lot of mitochondria in it, thus susceptible to damages done by 
mtDNA defects9, 18). Retina pigmentation was the most common 
pathologic finding noted among our patients during the OE. It is 
inferred that hypoxic environments due to mtDNA defects cause 
mitochondrial oxidative stresses and induce reactive oxygen species. 
This accelerates mtDNA damage which then leads to retinal 
degeneration18­20).
In this study, we grouped our patients based on their fundus 
examination results to find out the factors related to ocular 
involvement in MD. Regarding patients’ demographics of age, sex 
and so forth, there was no particular difference between groups 
with or without ocular involvement. Prematurity was the only 
factor among the birth histories that was significantly higher in the 
abnormal OE group. As for clinical manifestations, the number of 
frequent apnea events was also significantly higher in the abnormal 
OE group. It has been reported that frequent apnea events can 
occur more commonly in patients prematurely born, and hypoxic 
damage during apnea episodes might have been related with 
abnormal ophthalmologic findings21). Among the neurological 
symptoms, epilepsy was the only symptom with significantly higher 
prevalence in the abnormal OE group, which supports the need for 
more active OE when epilepsy is present. 
It has been reported many times that abnormal findings are 
Table 4. Metabolic Screening Test, Morphological Analysis, and 
Biochemical Enzyme Assay of Mitochondrial Disease Patients
 
Abnormal 
OE group 
(n=36) (%)
Normal 
OE group
(n=38) (%)
Total 
(%)
P-
value
Lactic acidosis
Increased lactate/pyruvate ratio
Increased CSF lactate (N=43)
Abnormal urine organic acid assay
Abnormal plasma amino acid
  assay
Abnormal light microscopic 
  findings
Abnormal electron microscopic 
  findings
MRC complex defect
    complex I 
    complex II
    complex IV
28 (77.8)
17 (47.2)
  8 (32.0)
17 (47.2)
16 (44.4)
13 (36.1)
15 (44.1)
31 (86.1)
  1 (  2.8)
 4 (11.1)
32 (84.2)
24 (63.2)
11 (61.1)
13 (34.2)
13 (34.2)
  6 (15.8)
13 (35.1)
31 (81.6)
  1 (  2.6)
  6 (15.8)
60 (81.1)
41 (55.4)
19 (44.2)
30 (40.5)
29 (39.2)
19 (25.7)
28 (39.4)
62 (83.8)
  2 (  2.7)
10 (13.5)
0.480
0.168
0.058
0.255
0.367
<0.05
0.439
0.597
1.000
0.737
Abbreviations: CSF, cerebrospinal fluid; MRC, mitochondrial respiratory chain 
complex
Table 5. Magnetic Resonance Imaging (MRI) and Magnetic Resonance 
Spectroscopy (MRS) Findings of Mitochondrial Disease Patients
 
Abnormal 
OE group 
(n=36) (%)
Normal 
OE group
(n=38) (%)
Total 
(%)
P-
value
MRI finding
  Thalamic hyperintensity
  Brainstem hyperintensity
  Cerebellar atrophy
  Infarction
  White matter hyperintensity
  Diffuse cerebral atrophy
  Basal ganglion hyperintensity
Lactate peak in MRS (N=72)
  8 (2 2.2)
  9 (25.0)
11 (30.6)
  3 (  8.3)
14 (38.9)
24 (66.7)
15 (41.7)
21 (60.0)
  7 (18.4)
  2 (  5.2)
  7 (18.4)
  8 (21.0)
11 (29.0)
11 (29.0)
13 (34.2)
13 (35.1)
15 (20.3)
11 (14.9)
18 (24.3)
11 (14.9)
25 (33.8)
35 (47.3)
28 (37.8)
34 (47.2)
0.684
<0.05
0.224
0.124
0.366
<0.05
0.509
<0.05
Abbreviations: MRI, magnetic resonance imaging; MRS: magnetic resonance 
spectroscopy
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observed more frequently under electron microscopy than under 
light microscopy in cases of pediatric MD4, 16, 22). We also had 
similar results with our patients and abnormal findings were noticed 
more often under electron microscopy. But, in our morphological 
analysis, abnormal findings were observed significantly more 
often under the light microscopy in the abnormal OE group, but 
there was no significant difference under the electron microscopy 
between the two groups. Therefore, it is important that when 
abnormal findings by the light microscopic examination, such as 
ragged red fibers, are seen in patients with MD, a more extensive 
OE should be performed regardless of the symptoms.
Like in other previous studies, diffuse cerebral atrophy was the 
most frequent finding in the MRI study among our patients23­25). 
In addition, brainstem hyperintensity was identified significantly 
more frequently in the abnormal OE group. It is presumed that 
since ophthalmologic symptoms are likely to be produced through 
the dysfunction of cranial nerves connected to the brainstem, 
patients with ophthalmologic symptoms more often showed 
hyperintensitiy in the corresponding area. In MRS, lactate peaks 
showed statistically significant correlation to ocular involvement. 
An increase in CSF lactate rather than serum lactate, and also 
the detection of lactate peaks in MRS rather than increase in 
CSF lactate, showed a more significant relationship to ocular 
involvement. This might have resulted due to tissue specificity2, 17, 18).
However, this study has some limitations. The research was 
conducted based on relatively small samples because of the rarity 
of the disease. The scarcity of MD made it difficult to design a 
prospective study. But if we consider that MD shows a variety 
of symptoms in several organs and ocular involvement is one of 
the key symptoms, an OE should always be required, even when 
the symptoms are not as distinctive. In short, when MD patients 
have a premature birth history, a history of epilepsy or frequent 
apnea events, abnormal light microscopic findings in the muscle 
pathology, diffuse cerebral atrophy in MRI, and brainstem 
hyperintensity and lactate peaks in MRS, active examinations 
and diagnoses should always be considered because the possibility 
of ocular involvement could be higher in such situations. Further 
prospective studies on more patients are expected in future. 
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